Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22136381 | 0.85 | LMNA (0.82) | LMNAHPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL1406772 | 0.81 | LMNA (0.56) | LMNAHPGDRXRARXRBRXRG | |
| SCHEMBL31055964 | 0.81 | LMNA (0.62) | LMNAHPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL16055179 | 0.81 | HPGD (0.62) | LMNAHPGDMRGPRX4MEN1KMT2A | |
| SCHEMBL10322959 | 0.79 | TPMT (0.49) | LMNATSHRALDH1A1TNFRSF1A | |
| SCHEMBL5364510 | 0.79 | RXRA (0.60) | LMNAHPGDRXRARXRBRXRG | |
| SCHEMBL11522243 | 0.78 | HPGD (0.52) | LMNAHPGDRXRARXRBRXRG | |
| SCHEMBL16250484 | 0.77 | LMNA (1.00) | LMNAHPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL2338199 | 0.76 | HPGD (0.76) | LMNAHPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL5369726 | 0.76 | MAOA (0.46) | LMNAHPGDRXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513793-B1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2011-03-09 | — | — | EP | disclosed |
| US-7468457-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-23 | — | — | US | disclosed |
| CN-1659132-A | Novel ligands as RAR receptor inhibitors, process for their preparation and their use in human medicine and cosmetics | GALDERMA RES & DEV (FR) | 2005-08-24 | — | — | CN | disclosed |
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | US | disclosed |
| EP-1513793-A1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003101928-A1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | LMNA 3807/4885HPGD 2268/4885RXRA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.